Finally, the largest cohort study that has evaluated the safety of preoperative anti-TNF, vedolizumab, or ustekinumab treatments in IBD patients concluded that none of these drugs increased the risk of postoperative complications [351]. This evidence concerns the gene TNF and inflammatory bowel disease.